Ganirelix
Ganirelix acetate, Org 37462
Ganirelix is a synthetic decapeptide GnRH receptor antagonist used in assisted reproduction to prevent premature ovulation during controlled ovarian stimulation. It is distinguished within the class by its two diethyl-homoarginine residues. Alongside cetrorelix it displaced the older agonist long protocols in many fertility centres, principally on grounds of safety and convenience rather than higher pregnancy rates.
Mechanism
Ganirelix competitively blocks the GnRH receptor on pituitary gonadotroph cells. Because it occupies the receptor without activating it, endogenous GnRH is displaced and LH and FSH secretion decline within hours: no stimulatory flare, and full reversibility once the drug is cleared. The molecular design combines the N-terminal antagonist cluster common to modern GnRH antagonists (3-(2-naphthyl)-D-alanine, 4-chloro-D-phenylalanine and 3-(3-pyridyl)-D-alanine) with an unusual feature: bulky N,N-diethyl-homoarginine residues at both position 6 and position 8. These sterically demanding side chains confer high receptor affinity and resistance to enzymatic degradation while altering the basic-residue arrangement responsible for the histamine release that limited earlier antagonist generations.
Clinically the point of ganirelix is timing control. During ovarian stimulation with exogenous FSH, rising oestradiol from multiple developing follicles can provoke a spontaneous LH surge that triggers ovulation before oocytes can be retrieved, wasting the cycle. Because ganirelix acts within hours, it need not be started until follicles approach the size at which that risk emerges, typically around day 5 or 6 of stimulation. This spares the one-to-three week downregulation phase required by agonist long protocols. As with cetrorelix, the pituitary is blocked rather than desensitised, so it retains the capacity to respond to a GnRH agonist trigger, the strategy used to induce final oocyte maturation with a short-lived endogenous LH surge in women at high risk of ovarian hyperstimulation syndrome.
What the research shows
The registration trial, conducted by the European Orgalutran Study Group, randomised 730 women undergoing ovarian stimulation with recombinant FSH, in a 2:1 ratio, to ganirelix or a long protocol of intranasal buserelin. It was designed as a non-inferiority study, and the results deserve careful reading rather than promotional summary. Ongoing pregnancy per attempt was 20.3 per cent with ganirelix versus 25.7 per cent with buserelin, and implantation was 15.7 versus 21.8 per cent, numerically lower with the antagonist, within the prespecified non-inferiority margin but not a demonstration of equivalence in the everyday sense. What ganirelix delivered instead was a markedly shorter treatment course, fewer injections, less recombinant FSH, and ovarian hyperstimulation syndrome in 2.4 per cent versus 5.9 per cent, less than half the rate. The trial's own title emphasised effectiveness, safety and convenience, and the convenience and safety claims were the better supported.
The subsequent literature has largely resolved the efficacy question in the antagonists' favour, though not by showing superiority. The Cochrane review of GnRH antagonists for assisted reproductive technology pooled a substantial body of randomised trials and found live birth rates comparable between antagonist and agonist long protocols, with a consistent and substantial reduction in ovarian hyperstimulation syndrome. The apparent pregnancy rate deficit visible in the earliest trials attenuated as clinicians gained experience with antagonist timing and as trial numbers grew. Smaller randomised comparisons in specific populations, such as women with polycystic ovary syndrome who are at particular hyperstimulation risk, have generally supported antagonist protocols in that group, though these individual trials are small and should not be over-weighted.
Evidence assessment
High-quality evidence
Ganirelix holds FDA approval (1999) and EU approval (2000) with regulator-reviewed labelling, granted on the basis of a large multicentre randomised controlled trial against the standard agonist long protocol. The antagonist class has since been evaluated across many randomised trials pooled in a Cochrane systematic review. Approved labelling plus replicated randomised evidence satisfies the strong criterion. AUDIT NOTE: all three PMIDs verified against PubMed, and every numerical result quoted from the pivotal trial was checked against the published abstract and matches exactly. A draft claim that some presentations contain natural rubber latex in the needle shield could not be confirmed and has been removed.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial Preclinical only
Ongoing pregnancy per attempt was 20.3 per cent with ganirelix versus 25.7 per cent with buserelin and implantation 15.7 versus 21.8 per cent, numerically lower but within the non-inferiority margin. Ovarian hyperstimulation syndrome occurred in 2.4 versus 5.9 per cent, with fewer injections and less FSH required.
Gonadotrophin-releasing hormone antagonists for assisted reproductive technology Preclinical only
Live birth rates were comparable between antagonist and agonist protocols, while ovarian hyperstimulation syndrome including severe cases was substantially reduced with antagonists. The early apparent pregnancy rate deficit attenuated as evidence accumulated.
Comparison of GnRH antagonist with long GnRH agonist protocol after OCP pretreatment in PCOs patients Preclinical only
Antagonist protocols performed comparably in a population at particularly high risk of ovarian hyperstimulation. A small single-centre trial that should be weighted accordingly rather than treated as definitive.
Safety
Ganirelix is generally well tolerated, and the most frequent adverse effect is a local injection site reaction: redness and swelling, usually mild and short-lived. Headache, nausea and malaise are reported. Hypersensitivity reactions including rare anaphylactoid events have occurred, and labelling notes caution in women with known hypersensitivity to GnRH analogues. The principal safety consideration, as with cetrorelix, is the context rather than the drug: ovarian stimulation carries a risk of ovarian hyperstimulation syndrome, which in severe form causes ascites, haemoconcentration, thromboembolism and, rarely, death. Ganirelix protocols roughly halve that risk relative to agonist long protocols but do not eliminate it, and enabling a GnRH agonist trigger reduces it further in high responders. Ganirelix is contraindicated in pregnancy and in women with known hypersensitivity to the active substance or to any GnRH analogue. It should be used only under the supervision of clinicians experienced in fertility treatment, since correct timing relative to follicular development is essential to both efficacy and safety.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | Licensed prescription-only medicine (POM), originally authorised via the European Medicines Agency in 2000 and now regulated in the United Kingdom by the MHRA, for prevention of premature ovulation in women undergoing controlled ovarian stimulation. |
| United States | Approved by the FDA in 1999. Prescription-only, licensed for the inhibition of premature luteinising hormone surges in women undergoing controlled ovarian hyperstimulation. |
| WADA (sport) | Not listed on the WADA Prohibited List. GnRH antagonists suppress rather than stimulate gonadotrophin secretion and therefore fall outside the section S2 prohibition covering GnRH agonist analogues. |
Questions
No. The pivotal trial actually showed numerically lower ongoing pregnancy and implantation rates than the buserelin long protocol, within the non-inferiority margin, and the Cochrane review found live birth rates comparable. Ganirelix's real advantages are a shorter cycle, fewer injections, less gonadotrophin, and roughly half the rate of ovarian hyperstimulation syndrome.
They are close pharmacological siblings. Both are decapeptide GnRH antagonists sharing the same N-terminal design and used for the same purpose. The main structural difference is that ganirelix carries diethyl-homoarginine residues at positions 6 and 8 where cetrorelix has D-citrulline and arginine. Head-to-head trials have not shown a clinically important difference between them.
Because it works within hours rather than weeks. As a receptor blocker it needs no desensitisation period, so it is introduced only when follicles approach the size at which a spontaneous LH surge becomes a real risk, usually around day 5 or 6. Agonist long protocols require one to three weeks of downregulation before stimulation can even begin.
It reduces the risk rather than causing it. Hyperstimulation is driven by the ovarian response to gonadotrophin stimulation, not by the antagonist. In the pivotal trial, hyperstimulation occurred in 2.4 per cent of ganirelix cycles versus 5.9 per cent with the agonist protocol, and the ability to use an agonist trigger in antagonist cycles lowers the risk further in high responders.